Telisotuzumab vedotin Disease Interactions
There are 4 disease interactions with telisotuzumab vedotin.
Telisotuzumab vedotin-tllv (applies to telisotuzumab vedotin) hepatic dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Telisotuzumab vedotin-tllv has not been studied in patients with moderate or severe hepatic dysfunction.
Telisotuzumab vedotin-tllv (applies to telisotuzumab vedotin) interstitial lung disease or pneumonitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Interstitial Pneumonitis
Interstitial lung disease or pneumonitis has occurred in patients treated with telisotuzumab vedotin-tllv. Patients should be monitored for new or worsening respiratory symptoms.
Telisotuzumab vedotin-tllv (applies to telisotuzumab vedotin) peripheral neuropathy
Moderate Potential Hazard, Moderate plausibility.
Peripheral neuropathy, including peripheral sensory neuropathy and peripheral motor neuropathy has occurred in patients treated with telisotuzumab vedotin-tllv. Patients should be monitored for signs and symptoms of new or worsening peripheral neuropathy such as hypoesthesia, hyperesthesia, paresthesia, a burning sensation, neuropathic pain, or muscle weakness.
Telisotuzumab vedotin-tllv (applies to telisotuzumab vedotin) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Telisotuzumab vedotin-tllv has not been studied in patients with severe renal dysfunction, and end-stage renal disease with or without dialysis.
Switch to professional interaction data
Telisotuzumab vedotin drug interactions
There are 381 drug interactions with telisotuzumab vedotin.
Report options
More about telisotuzumab vedotin
- telisotuzumab vedotin consumer information
- Check interactions
- Compare alternatives
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat advanced non-small cell lung cancer (NSCLC) in adults that has certain ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Docetaxel
Docetaxel is used for breast cancer, breast cancer, metastatic, gastric cancer, head and neck ...
Nivolumab
Nivolumab is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
